CDMOs turn to pharma facility acquisitions amid manufacturing realignment: GlobalData
A wave of facility sales to CDMOs reflects shifting manufacturing strategies as drugmakers expand U.S. production and outsourcing partners scale capacity, the firm says.
Read the full article on the original site.
Read Full Article